hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06285032, orgStudyIdInfo id: STUDY00017244, secondaryIdInfos id: R34DA058325, type: NIH, link: https://reporter.nih.gov/quickSearch/R34DA058325, briefTitle: Decreasing Loneliness to Optimize Pain Care, acronym: DLoop, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03, primaryCompletionDateStruct date: 2025-03, completionDateStruct date: 2026-05, studyFirstPostDateStruct date: 2024-02-29, lastUpdatePostDateStruct date: 2024-03-01, sponsorCollaboratorsModule leadSponsor name: University of Washington, class: OTHER, collaborators name: National Institute on Drug Abuse (NIDA), descriptionModule briefSummary: Loneliness, which is the perceived feeling of insufficient personal relationships, is related to higher risk for inappropriate opioid use and opioid use disorders in patients who are taking opioids long-term. The study seeks to pilot test the evidence-based loneliness interventions of psychological therapy and social navigation in patients on chronic opioids treated in primary care practices to determine if reducing loneliness can lower opioid misuse., conditionsModule conditions: Loneliness, conditions: Opioid Use, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: OTHER, maskingInfo masking: NONE, enrollmentInfo count: 102, type: ESTIMATED, armsInterventionsModule interventions name: Cognitive Behavior Therapy (CBT), interventions name: Social Navigation Group, interventions name: Controlled Group, outcomesModule primaryOutcomes measure: Opioid Misuse, secondaryOutcomes measure: Determine Functional Outcome, otherOutcomes measure: Loneliness, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University of Washington, city: Seattle, state: Washington, zip: 98105, country: United States, geoPoint lat: 47.60621, lon: -122.33207, hasResults: False
protocolSection identificationModule nctId: NCT06285019, orgStudyIdInfo id: GWK-2023-004, briefTitle: Modified TOMOX-HAIC in Combination With Sintilimab and Bevacizumab Biosimilar for First-line Treatment of Advanced Hepatocellular Carcinoma, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-12-01, primaryCompletionDateStruct date: 2024-12-31, completionDateStruct date: 2025-12-31, studyFirstPostDateStruct date: 2024-02-29, lastUpdatePostDateStruct date: 2024-02-29, sponsorCollaboratorsModule leadSponsor name: Fudan University, class: OTHER, descriptionModule briefSummary: This is a single-center, single-arm, phase II clinical study, to explore the efficacy and safety of modified TOMOX-HAIC combined with sintilimab and bevacizumab biosimilar as first line treatment in patients with advanced hepatocellular carcinoma., conditionsModule conditions: Hepatocellular Carcinoma, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 65, type: ESTIMATED, armsInterventionsModule interventions name: TOMOX-HAIC, interventions name: Sintilimab, interventions name: Bevacizumab, outcomesModule primaryOutcomes measure: objective response rate (ORR), secondaryOutcomes measure: disease control rate (DCR), secondaryOutcomes measure: Progression-Free Survival (PFS), secondaryOutcomes measure: Time to progression (TTP), secondaryOutcomes measure: Duration of response (DOR), secondaryOutcomes measure: overall survival (OS), secondaryOutcomes measure: adverse event (AE), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Fudan University Shanghai Cancer Center, status: RECRUITING, city: Shanghai, state: Shanghai, zip: 200062, country: China, contacts name: Lu Wang, M.D., role: CONTACT, phone: +86-18121299357, email: w.lr@hotmail.com, geoPoint lat: 31.22222, lon: 121.45806, hasResults: False
protocolSection identificationModule nctId: NCT06285006, orgStudyIdInfo id: MScAZASTPED025/23/202/12/2021, briefTitle: Desmopressin Monotherapy for Monosymptomatic Nocturnal Enuresis, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-23, primaryCompletionDateStruct date: 2024-05-01, completionDateStruct date: 2024-05-12, studyFirstPostDateStruct date: 2024-02-29, lastUpdatePostDateStruct date: 2024-04-23, sponsorCollaboratorsModule leadSponsor name: Al-Azhar University, class: OTHER, descriptionModule briefSummary: Nocturnal Enuresis (NE) is defined as the involuntary passage of urine during sleep past the age of usual control, which is considered a developmental age of 5 to 7 years.NE is a common problem that causes distress to both children and their families. It has an adverse impact on behavior and social life, affects self-esteem, and can result in poor emotional well-being. In Egypt, the prevalence of NE in primary school children is about 15.4%. The family history was seen to have had a markedly significant impact on the occurrence of NE in the studied children. The mainstay of treatment is urotherapy with information and psychoeducation about normal lower urinary tract function, the underlying cause of MNE, disturbed bladder dysfunction in the child with NMNE, and instructions about therapeutic strategies. Alarm therapy and desmopressin are effective in randomized trials. Children with NMNE first need treatment of the underlying daytime functional bladder problem before treatment of nocturnal enuresis., conditionsModule conditions: Nocturnal Enuresis, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: Desmopressin, outcomesModule primaryOutcomes measure: The number of episodes per week after desmopressin treatment, eligibilityModule sex: ALL, minimumAge: 7 Years, maximumAge: 14 Years, stdAges: CHILD, contactsLocationsModule locations facility: Alazhar university, status: RECRUITING, city: Assiut, zip: 11884, country: Egypt, contacts name: Omnia Nassar, Dr, role: CONTACT, phone: 01010112054, email: omnianassar835@gmail.com, contacts name: Hosny Elmasry, Prof, role: CONTACT, phone: 01010112054, email: omnianassar835@gmail.com, geoPoint lat: 27.18096, lon: 31.18368, hasResults: False
protocolSection identificationModule nctId: NCT06284980, orgStudyIdInfo id: 2369, briefTitle: Gestional Trophoblastic Neoplasia Ultrasound Assessment: Titanium Study, acronym: TITANIUM, statusModule overallStatus: RECRUITING, startDateStruct date: 2019-01-24, primaryCompletionDateStruct date: 2024-12-30, completionDateStruct date: 2025-12-31, studyFirstPostDateStruct date: 2024-02-29, lastUpdatePostDateStruct date: 2024-02-29, sponsorCollaboratorsModule leadSponsor name: Fondazione Policlinico Universitario Agostino Gemelli IRCCS, class: OTHER, descriptionModule briefSummary: Gestational trophoblast diseases are characterized by abnormal proliferation of trophoblastic tissue, which can occur consequent to any pregnancy event. Pre-malignant forms (partial hydatiform mola and complete mola) and malignant forms are distinguished, the latter also known as gestational trophoblast neoplasms (invasive hydatiform mola, choriocarcinoma, placental site trophoblastic tumor, and epithelioid trophoblastic tumor).These are neoplasms associated with good prognosis, amenable to conservative treatment and highly sensitive to chemotherapy.The identification of ultrasonographic and echofluximetric features typical of malignant forms as well as the identification of ultrasonographic parameters predictive of chemoresistance to single-drug treatments could help improve their management., conditionsModule conditions: Describe Typical Gray Scale/Color Doppler Ultrasound Features of Gestational Trophoblastic Neoplasia at the US Examination, conditions: To Assess if There Are Differences at the Baseline US Scan Between Low-risk and High-risk Patients, conditions: To Identify Ultrasound Predictors of Resistance to First-line Single Drug Chemotherapy in Low-risk GTN Patients, conditions: To Investigate if Machine Learning (ML) Algorithms (Radiomics, Deep Neural Networks (DNN), and Other Machine Learning Algorithms, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: PROSPECTIVE, enrollmentInfo count: 120, type: ESTIMATED, outcomesModule primaryOutcomes measure: typical features of Gestational Trophoblastic Neoplasia, secondaryOutcomes measure: differences at the baseline US scan between low-risk and high-risk patients, otherOutcomes measure: changes characteristics of Gestational Trophoblastic Neoplasia during treatment, eligibilityModule sex: FEMALE, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, status: RECRUITING, city: Rome, zip: 00168, country: Italy, contacts name: Floriana Mascilini, role: CONTACT, phone: 0630156399, email: floriana.mascilini@policlinicogemelli.it, geoPoint lat: 41.89193, lon: 12.51133, hasResults: False
protocolSection identificationModule nctId: NCT06284967, orgStudyIdInfo id: Vitamin D In Spondylolysis, briefTitle: Association Of Serum Vitamin D Level With Isthmic Spondylolysis, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03, primaryCompletionDateStruct date: 2025-08-01, completionDateStruct date: 2025-09-01, studyFirstPostDateStruct date: 2024-02-29, lastUpdatePostDateStruct date: 2024-03-08, sponsorCollaboratorsModule leadSponsor name: Assiut University, class: OTHER, descriptionModule briefSummary: The aim of this study is to compare vitamin D level between young adults with isthmic spondylolysis and a matched healthy control group., conditionsModule conditions: Spondylolysis, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: PROSPECTIVE, enrollmentInfo count: 184, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: Mean serum vitamin D in both groups., secondaryOutcomes measure: Mean serum calcium level, eligibilityModule sex: ALL, minimumAge: 20 Years, maximumAge: 45 Years, stdAges: ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06284954, orgStudyIdInfo id: ARGX-117-2301, secondaryIdInfos id: 2023-508337-14, type: OTHER, domain: CTIS number, briefTitle: A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis, acronym: empacific, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-10, primaryCompletionDateStruct date: 2025-07-18, completionDateStruct date: 2028-01-20, studyFirstPostDateStruct date: 2024-02-29, lastUpdatePostDateStruct date: 2024-03-15, sponsorCollaboratorsModule leadSponsor name: argenx, class: INDUSTRY, descriptionModule briefSummary: This study will evaluate the safety and efficacy of empasiprubart compared with placebo in adult participants with dermatomyositis (DM)., conditionsModule conditions: Dermatomyositis, conditions: Myositis, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 80, type: ESTIMATED, armsInterventionsModule interventions name: Empasiprubart IV, interventions name: Placebo IV, outcomesModule primaryOutcomes measure: Incidence and severity of adverse events (AEs), primaryOutcomes measure: Percentage of participants discontinuing investigational medicinal product (IMP) due to an adverse event (AE), secondaryOutcomes measure: Mean TIS, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06284941, orgStudyIdInfo id: KY 2023-001-001, briefTitle: A Study of Ropivacaine Complex Methylene Blue Fascia Iliaca Compartment Block on Analgesia in Patients Undergoing Hip Arthroplasty, statusModule overallStatus: ENROLLING_BY_INVITATION, startDateStruct date: 2023-06-20, primaryCompletionDateStruct date: 2024-06-20, completionDateStruct date: 2024-06-20, studyFirstPostDateStruct date: 2024-02-29, lastUpdatePostDateStruct date: 2024-02-29, sponsorCollaboratorsModule leadSponsor name: Wang wanxia, class: OTHER, descriptionModule briefSummary: Total hip arthroplasty is currently the most effective method for treating hip joint lesions and improving quality of life, but postoperative severe pain is not conducive to rapid recovery of patients. In recent years, the widespread application of ultrasound has achieved good clinical results in iliac fascia block for postoperative analgesia in THA. However, the use of high-dose local anesthetics can increase the risk of local anesthetic poisoning, and the single block analgesia time is generally less than 24 hours. Methylene blue, as a long-acting analgesic drug, can block the pain transmission of nerve fibers for a long time, achieving analgesic effects without damaging neurons. This study used ultrasound-guided ropivacaine combined with methylene blue to perform iliac fascia block on patients undergoing total hip replacement, with the aim of prolonging pain relief time, reducing complications, and promoting postoperative recovery on the basis of traditional methods., conditionsModule conditions: Femoral Neck Disease, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: OTHER, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 90, type: ESTIMATED, armsInterventionsModule interventions name: Ropivacaine combined with methylene blue for iliac fascia block, outcomesModule primaryOutcomes measure: Neutrophil lymphocyte ratio, primaryOutcomes measure: visual analogue scale（VAS）, primaryOutcomes measure: Procalcitonin, primaryOutcomes measure: Hypersensitive C-reactive protein, secondaryOutcomes measure: Mean arterial pressure, secondaryOutcomes measure: Heart rate, secondaryOutcomes measure: Duration of surgery, secondaryOutcomes measure: Number of postoperative salvage analgesia, secondaryOutcomes measure: Walking distance for the first time getting out of bed, secondaryOutcomes measure: The number of activities of getting out of bed 48 hours after surgery, eligibilityModule sex: ALL, minimumAge: 65 Years, maximumAge: 85 Years, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Jiangyan District Hospital of traditional Chinese medicine attached to the Nanjing University of Chinese Medicine, city: Taizhou, state: Jiang Su, zip: 225500, country: China, geoPoint lat: 32.49069, lon: 119.90812, hasResults: False
protocolSection identificationModule nctId: NCT06284928, orgStudyIdInfo id: 20240104-01, briefTitle: Gut Microbiota and New Hypertension, acronym: MIPHYP-CROSS, statusModule overallStatus: COMPLETED, startDateStruct date: 2019-12-01, primaryCompletionDateStruct date: 2020-06-01, completionDateStruct date: 2020-12-01, studyFirstPostDateStruct date: 2024-02-29, lastUpdatePostDateStruct date: 2024-02-29, sponsorCollaboratorsModule leadSponsor name: Xinjiang Medical University, class: OTHER, descriptionModule briefSummary: This study aims to explore the gut microbiota patterns in patients newly diagnosed with hypertension, comparing them to those in non-hypertensive individuals. Utilizing cross-sectional analysis, it seeks to identify specific microbial profiles associated with hypertension, which could provide insights into the disease's pathogenesis and potential new avenues for treatment. The research focuses on analyzing fecal samples collected from both groups, using advanced genomic techniques to assess the diversity and abundance of gut bacteria. This investigation could contribute significantly to our understanding of the role gut microbiota plays in cardiovascular health and disease., conditionsModule conditions: Hypertension, conditions: Gut Microbiota, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CROSSOVER, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 100, type: ACTUAL, armsInterventionsModule interventions name: Gut Microbiota Analysis, outcomesModule primaryOutcomes measure: Change in Gut Microbiota Composition, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: The First Affiliated Hospital of Xinjiang Medical University, city: Ürümqi, state: Xinjiang, zip: 630000, country: China, geoPoint lat: 43.80096, lon: 87.60046, hasResults: False
protocolSection identificationModule nctId: NCT06284902, orgStudyIdInfo id: BDR17987, briefTitle: Bioavailability Study of Fexofenadine HCl New Formulation Tablet, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-23, primaryCompletionDateStruct date: 2024-05-08, completionDateStruct date: 2024-05-23, studyFirstPostDateStruct date: 2024-02-29, lastUpdatePostDateStruct date: 2024-03-21, sponsorCollaboratorsModule leadSponsor name: Opella Healthcare Group SAS, a Sanofi Company, class: INDUSTRY, descriptionModule briefSummary: The purpose of the study is to assess the relative bioavailability of a new galenic form of fexofenadine HCl new formulation tablet (test drug) taken with or without water compared to fexofenadine HCl film-coated tablets (reference form) taken with water under fasting conditions., conditionsModule conditions: Healthy Volunteers, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 25, type: ESTIMATED, armsInterventionsModule interventions name: Fexofenadine HCl Coated tablet, interventions name: Fexofenadine HCl New Formulation Tablet, outcomesModule primaryOutcomes measure: Area Under the Concentration-time Curve From Time Zero Until the Last Observed Concentration (AUC0-t) of Fexofenadine, primaryOutcomes measure: Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated) (AUC0-inf) of Fexofenadine, primaryOutcomes measure: Maximal Observed Concentration (Cmax) of Fexofenadine, secondaryOutcomes measure: Time When the Maximal Concentration is Observed (Tmax) of Fexofenadine, secondaryOutcomes measure: Time of Observation Prior to the First Observation with a Measurable (non-zero) Concentration (Tlag) of Fexofenadine, secondaryOutcomes measure: Terminal Half-life Associated with the Terminal Slope (T1/2z) of Fexofenadine, secondaryOutcomes measure: Terminal Elimination Rate Constant (Kel) of Fexofenadine, secondaryOutcomes measure: Percentage of Participants with Treatment Emergent Adverse Events (TEAEs), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 55 Years, stdAges: ADULT, contactsLocationsModule locations facility: Syneos Health Clinic inc., status: RECRUITING, city: Quebec, zip: G1P 0A2, country: Canada, geoPoint lat: 46.81228, lon: -71.21454, hasResults: False
protocolSection identificationModule nctId: NCT06284876, orgStudyIdInfo id: IY-NTNS03, briefTitle: Study to Evaluate the Efficacy and Safety of Ilaprazole 10 mg in Prevention NSAIDs Associated Peptic Ulcer, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-08-30, primaryCompletionDateStruct date: 2026-08-30, completionDateStruct date: 2027-02-28, studyFirstPostDateStruct date: 2024-02-29, lastUpdatePostDateStruct date: 2024-02-29, sponsorCollaboratorsModule leadSponsor name: Il-Yang Pharm. Co., Ltd., class: INDUSTRY, descriptionModule briefSummary: To demonstrate the non-inferiority of Ilaprazole 10 mg to the active control in prevention of NSAIDs-associated peptic ulcer, as assessed by the proportion of subjects with peptic ulcer by Week 24, conditionsModule conditions: Peptic Ulcer, designModule studyType: INTERVENTIONAL, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 416, type: ESTIMATED, armsInterventionsModule interventions name: Ilaprazole, interventions name: Lansoprazole, interventions name: Ilaprazole Placebo, interventions name: Lansoprazole Placebo, outcomesModule primaryOutcomes measure: Ilaprazole, Lansoprazole peptic ulcer, secondaryOutcomes measure: Ilaprazole, Lansoprazole peptic ulcer, secondaryOutcomes measure: Ilaprazole, Lansoprazole GI bleeding, eligibilityModule sex: ALL, minimumAge: 19 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Chung Ang University Hospital, city: Seoul, country: Korea, Republic of, geoPoint lat: 37.566, lon: 126.9784, hasResults: False
protocolSection identificationModule nctId: NCT06284863, orgStudyIdInfo id: 04-2023-200315, briefTitle: Impact Of Nutritional Education Program In Hemodialysis Patients, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03, primaryCompletionDateStruct date: 2025-03, completionDateStruct date: 2026-04, studyFirstPostDateStruct date: 2024-02-29, lastUpdatePostDateStruct date: 2024-02-29, sponsorCollaboratorsModule leadSponsor name: Assiut University, class: OTHER, descriptionModule briefSummary: The study aims to improve the health status of chronic renal failure patients on hemodialysis using nutritional education program on quality of life anserum d electrolytes level by application of physical and clinical evaluation and some biochemical analysis before and after a specified nutritional program, conditionsModule conditions: Hemodialysis Complication, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: NONE, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: Natritional Education Program In Hemodialysis Patients, outcomesModule primaryOutcomes measure: The percentage patients responded to nutritional education program on hemodialysis patients., eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 60 Years, stdAges: ADULT, hasResults: False